SABCS 2023 – SERDs square off in combinations
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
Roche seeks alpha to defeat Novartis
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
Argenx’s efforts to Advance fall flat
Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.
A reprieve for Blenrep?
Against the odds GSK’s Dreamm-7 study yields a positive survival readout.
ASH 2023 preview – Darzalex gets a first-line boost from Perseus
But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?
